148 related articles for article (PubMed ID: 38230711)
1. The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer's Biomarker Results to Research Participants.
Erickson CM; Chin NA; Ketchum FB; Eveler ML; Conway CE; Coughlin DM; Clark LR
J Prev Alzheimers Dis; 2024; 11(1):1-6. PubMed ID: 38230711
[TBL] [Abstract][Full Text] [Related]
2. Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.
Ketchum FB; Chin NA; Grill J; Gleason CE; Erickson C; Clark LR; Paulsen JS; Kind AJH
Alzheimers Dement; 2022 Oct; 18(10):1969-1979. PubMed ID: 35213786
[TBL] [Abstract][Full Text] [Related]
3. Ethical Frameworks for Disclosure of Alzheimer Disease Biomarkers to Research Participants: Conflicting Norms and a Nuanced Policy.
Bunnik EM; Smedinga M; Milne R; Georges J; Richard E; Schermer MHN
Ethics Hum Res; 2022 Nov; 44(6):2-13. PubMed ID: 36316970
[TBL] [Abstract][Full Text] [Related]
4. Creating an Unprotected Class: Addressing Legal Risks in the Era of Biologically-Defined Alzheimer's Disease.
Vaishnav N; Gonzalez R; Karunungan K; Tyler A; Zheng W; Arias JJ
J Alzheimers Dis; 2024; 98(1):187-195. PubMed ID: 38393896
[TBL] [Abstract][Full Text] [Related]
5. Informing Disclosure: Efficacy of a Brief Educational Intervention on Research Participants' Knowledge about Alzheimer's Disease Biomarkers.
Ketchum FB; Erickson CM; Basche KE; Chin NA; Rosario HL; Johnson SC; Clark LR
J Alzheimers Dis; 2023; 96(2):515-522. PubMed ID: 37807783
[TBL] [Abstract][Full Text] [Related]
6. Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.
Bemelmans SA; Tromp K; Bunnik EM; Milne RJ; Badger S; Brayne C; Schermer MH; Richard E
Alzheimers Res Ther; 2016 Nov; 8(1):46. PubMed ID: 27832826
[TBL] [Abstract][Full Text] [Related]
7. Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know.
Erickson CM; Chin NA; Johnson SC; Gleason CE; Clark LR
Alzheimers Dement (Amst); 2021; 13(1):e12150. PubMed ID: 33665341
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohort.
Erickson CM; Chin NA; Rosario HL; Peterson A; Johnson SC; Clark LR
Alzheimers Dement (N Y); 2023; 9(3):e12413. PubMed ID: 37521522
[TBL] [Abstract][Full Text] [Related]
9. On the personal utility of Alzheimer's disease-related biomarker testing in the research context.
Bunnik EM; Richard E; Milne R; Schermer MHN
J Med Ethics; 2018 Dec; 44(12):830-834. PubMed ID: 30154216
[TBL] [Abstract][Full Text] [Related]
10. Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes.
Erickson CM; Ketchum FB; Basche KE; Chin NA; Eveler ML; Clark LR
Alzheimers Dement (N Y); 2024; 10(2):e12483. PubMed ID: 38882702
[TBL] [Abstract][Full Text] [Related]
11. Is Reluctance to Share Alzheimer's Disease Biomarker Status with a Study Partner a Barrier to Preclinical Trial Recruitment?
Cox CG; Ryan MM; Gillen DL; Grill JD
J Prev Alzheimers Dis; 2021; 8(1):52-58. PubMed ID: 33336225
[TBL] [Abstract][Full Text] [Related]
12. Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.
Molinuevo JL; Cami J; Carné X; Carrillo MC; Georges J; Isaac MB; Khachaturian Z; Kim SY; Morris JC; Pasquier F; Ritchie C; Sperling R; Karlawish J
Alzheimers Dement; 2016 May; 12(5):614-22. PubMed ID: 26988427
[TBL] [Abstract][Full Text] [Related]
13. Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum.
Largent EA; Grill JD; O'Brien K; Wolk D; Harkins K; Karlawish J
Neurology; 2023 May; 100(21):1010-1019. PubMed ID: 36720642
[TBL] [Abstract][Full Text] [Related]
14. Cognitively Healthy Individuals Want to Know Their Risk for Alzheimer's Disease: What Should We Do?
Stites SD
J Alzheimers Dis; 2018; 62(2):499-502. PubMed ID: 29480203
[TBL] [Abstract][Full Text] [Related]
15. Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society.
Erickson CM; Clark LR; Ketchum FB; Chin NA; Gleason CE; Largent EA
Alzheimers Dement (Amst); 2022; 14(1):e12339. PubMed ID: 36035626
[TBL] [Abstract][Full Text] [Related]
16. Post-disclosure distress among racial and ethnic groups in a preclinical AD trial.
Ritchie M; Salazar CR; Gillen DL; Grill JD
Alzheimers Dement; 2024 Apr; 20(4):2508-2515. PubMed ID: 38329007
[TBL] [Abstract][Full Text] [Related]
17. Anticipated reactions to learning Alzheimer's disease biomarker results.
Clark LR; Erickson CM; Jonaitis EM; Ma Y; Chin NA; Basche K; Ketchum FB; Gleason CE
Alzheimers Res Ther; 2022 Jun; 14(1):85. PubMed ID: 35733219
[TBL] [Abstract][Full Text] [Related]
18. Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial.
Grill JD; Raman R; Ernstrom K; Wang S; Donohue MC; Aisen PS; Karlawish J; Henley D; Romano G; Novak G; Brashear HR; Sperling RA
Neurol Clin Pract; 2024 Apr; 14(2):e200265. PubMed ID: 38585443
[TBL] [Abstract][Full Text] [Related]
19. The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research.
Ketchum FB; Chin NA; Erickson C; Lambrou NH; Basche K; Gleason CE; Clark L
Alzheimers Dement (N Y); 2023; 9(3):e12416. PubMed ID: 37583545
[TBL] [Abstract][Full Text] [Related]
20. Caregivers' attitude toward disclosure of Alzheimer's disease diagnosis in Urban China.
Zou Y; Song N; Hu YB; Gao Y; Zhang YQ; Zhao QH; Guo QH; Li X; Li GJ; Xiao SF; Chen SD; Ren RJ; Wang G
Int Psychogeriatr; 2017 Nov; 29(11):1849-1855. PubMed ID: 28660845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
